Forest, Daiichi Partner To Promote Hypertension Combo Azor Upon Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest will pay Daiichi $20 million up front and provide a minimum number of product details in return for annual co-promotion payment.
You may also be interested in...
Forest Ends Daiichi Azor Deal To Focus On Its Own Products
Japanese pharma gets $26 million break-up fee as co-promotion ends.
Forest Ends Daiichi Azor Deal To Focus On Its Own Products
Japanese pharma gets $26 million break-up fee as co-promotion ends.
Forest Hopeful No More Trials Needed For Milnacipran Fibromyalgia Filing
Priority review could bring the drug to market in June, at the same time competitor Lilly’s Cymbalta may be approved for the indication.